Avid Bioservices, Inc. and Humanigen, Inc. have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat the immune hyper-response, cytokine storm, associated with COVID-19. Humanigen completed enrollment of its 520 patient Phase 3 trial of lenzilumab in hospitali...